![[ Visit Client Website ]](images/banner.png)
Background: The non-nucleoside reverse transcriptase inhibitor efavirenz is recommended as part of first-line therapy in HIV-infected patients and prescribed at a standard dose of 600 mg once daily. EFV is extensively metabolized primarily by hepatic CYP2B6 with partial involvement of CYP3A4 and CYP2A6. The aim of the study was to assess CYP 2B6 G516T polymorphism and their impact in efavirenz based therapy
Methods: A computerized literature search was conducted using the Medline, PubMed, and High wire. Statistical analysis was conducted using comprehensive Meta analysis version 2 software.
Result: From fifty four articles only twenty two articles were included in the study based on the inclusion criteria. The average frequency of CYP 2B6 G516T polymorphism, from forest plot of 7 studies, was around 30% which strengthened the idea of substantial number of this polymorphism. Most of the studies had high proportion of mutant allele and the average of the all is around 49%. The mean plasma efavirenz concentration among 516GG, 516 GT and 516 TT holders was 2.869 ± 0.294 µg/ml, 3.464 ± 0.276 µg/ml and 9.659 ± 1.262 µg/ml, respectively and it has significant association with genetic polymorphism of CYP 2B6 G516T.
Conclusion: The most common type of CYP 2B6 polymorphism is CYP 2B6 G516T that have significant association with plasma efavirenz concentration. Having genetic test before drug starting is promising in HIV therapy to decrease side effects and to have better treatment outcome.
Keywords: CYP 2B6, efavirenz or polymorphism, and HIV/AIDS
Learning Objectives: at the end of the presentation participants are expected to assess and discuss the impact of polymorphism in antiretroviral drug treatment in both global aspect and in Ethiopian context. most importantly it analyze and describe CYP 2B6 polymorphism and the consequence in rise and down of plasma drug concentration that may associate to the adverse effect of the drug, the adherence, treatment outcome of the therapy.